This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Yemen

2. Grant Number: 1418-YEM-25c-X / 14-YEM-08h-Y

3. Date of Decision Letter: 01/07/2014

4. Date of the Partnership Framework Agreement: August 2014

5. Programme Title: NVS, IPV Routine

6. Vaccine type: Inactivated Polio Vaccine (IPV)

7. Requested product presentation and formulation of vaccine¹: Inactivated Polio Vaccine, 10 dose(s) per vial, LIQUID

8. Programme Duration²: 2014 - 2018

9. Programme Budget (indicative) (subject to the terms of the Partnership Framework Agreement): Please note that endorsed or approved amounts for 2017 and 2018 will be communicated in due course, taking into account updated information on country requirements and following GAVI’s review and approval processes.

<table>
<thead>
<tr>
<th>Programme Budget (US$)</th>
<th>2014</th>
<th>2015</th>
<th>2016</th>
<th>Total³</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>US$456,000</td>
<td>US$1,768,000</td>
<td>US$1,518,000</td>
<td>US$3,742,000</td>
</tr>
</tbody>
</table>

10. Vaccine Introduction Grant: US$614,000

¹ Please refer to section 18 for additional information on IPV presentation.
² This is the entire duration of the programme.
³ This is the total amount endorsed by GAVI for 2014 to 2016.
11. Indicative Annual Amounts (subject to the terms of the Partnership Framework Agreement):^4

<table>
<thead>
<tr>
<th>Type of supplies to be purchased with GAVI funds in each year</th>
<th>2014</th>
<th>2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of IPV vaccines doses</td>
<td>380,700</td>
<td>1,478,700</td>
</tr>
<tr>
<td>Number of AD syringes</td>
<td>251,300</td>
<td>942,500</td>
</tr>
<tr>
<td>Number of re-constitution syringes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of safety boxes</td>
<td>2,775</td>
<td>10,375</td>
</tr>
<tr>
<td>Annual Amounts (US$)</td>
<td>US$456,000</td>
<td>US$1,768,000</td>
</tr>
</tbody>
</table>

12. Procurement agency: UNICEF

13. Self-procurement: not applicable

14. Co-financing obligations:
   GAVI’s usual co-financing requirements do not apply to IPV. However, Yemen is encouraged to contribute to vaccine and/or supply costs for IPV.

15. Operational support for campaigns: N/A

16. The Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future Annual Amounts: The Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future Annual Amounts.

<table>
<thead>
<tr>
<th>Reports, documents and other deliverables</th>
<th>Due dates</th>
</tr>
</thead>
<tbody>
<tr>
<td>Annual Progress Report or equivalent</td>
<td>To be agreed with GAVI Secretariat in the context of GAMR Joint Appraisal for support in 2014.</td>
</tr>
</tbody>
</table>

17. Financial Clarifications: The Country shall provide the following clarifications to GAVI*:

*Failure to provide the financial clarifications requested may result in GAVI withholding further disbursements

18. Other conditions:

If Yemen envisages a switch in product presentation, it is encouraged to incorporate elements for both IPV presentations in your initial introduction preparations, in order to minimise the need for later

^4 This is the amount that GAVI has approved. Please amend the indicative Annual Amounts from previous years if that changes subsequently.
interventions and facilitate the switch. In those circumstances, in principle, no product switch grant will be provided to Yemen.

Signed by,

On behalf of the GAVI Alliance
Hind Khatib-Othman
Managing Director, Country Programmes
1 July 2014